Nexgen Biomedical, Inc. is an early stage company with two areas of development: 1) best in class protocols for S-Phase cytotoxic chemotherapeutics and 2) dermal and pulmonary antiproliferative, antiviral, and anti-inflammatory compounds based on RNAi / PSI technology.


BEST IN CLASS PROTOCOLS FOR S-PHASE CYTOTOXICS
(Tumor Specific Cell Cycle Synchronous Chemotherapy)

• Executive Summary

• Cell Cycle Synchronous Chemotherapy Slide Show (PDF)


RNAi / PSI DERMAL AND PULMONARY ANTIPROLIFERATIVE, ANTIVIRAL, AND ANTI-INFLAMMATORY COMPOUNDS

• Executive Summary

• RNAi / PSI Slide Show (PDF)

• Product / Clinical Data Summary (PDF)


THE TEAM


Contact Info: Mark Zamoyski, e-mail: mark@nexgen.biz, Tel: 408-365-1170


DISCLAIMER AND IMPORTANT NOTICE:The Compositions and Methods presented on this website are all in preclinical stages. They are based only on our understanding of the proposed underlying mechanisms of action and on any available coincidental corroborative empirical evidence, any of which may in fact turn out not to be correct, or may be prevented from functioning as envisioned because of other factors or mechanisms of action not contemplated or considered, or may even cause harm because of factors or mechanisms of action not anticipated. The process of obtaining FDA approvals has not been started in any of the areas disclosed on this website. The disclosures here are purely for scientific information exchange purposes, representing one scientific point of view, and are not intended to suggest, or be used for, any proposed medical treatments.


© 2002 - 2008 Mark Zamoyski & NexGen Biomedical, Inc.